Vera Therapeutics Inc - Ordinary Shares - Class A Stock
Vera Therapeutics Inc - Ordinary Shares - Class A Stock price
Key metrics
| Market capitalization | $2.93b |
| Enterprise Value | $2.63b |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | 8.81 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-145.28m |
| Cash position | $353.31m |
| EPS (TTM) EPS | $-2.60 |
| P/E forward | negative |
Is Vera Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Vera Therapeutics Inc - Ordinary Shares - Class A Stock Analysis
Analyst Opinions
10 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:
Analyst Opinions
10 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:
Financial data from Vera Therapeutics Inc - Ordinary Shares - Class A
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -145 -145 |
29%
29%
|
EBIT (Operating Income) EBIT | -145 -145 |
34%
34%
|
| Net Profit | -134 -134 |
31%
31%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Vera Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vera Therapeutics Inc - Ordinary Shares - Class A Stock News
Company Profile
Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Marshall Fordyce |
| Employees | 51 |
| Founded | 2016 |
| Website | www.veratx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
